The results of our IHC staining demonstrated that HLA-A and B2M protein loss occurred between 0-56% in diverse tumor types and subtypes with a higher frequency of B2M and HLA-A loss in metastatic specimens. The gene discussed is HLA-A; the disease is neoplasm.